Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.63 |
| ▸ | VEGFA | P15692 | 11/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770235 | 0.88 | EGLN1 (0.61) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL14900099 | 0.83 | EGLN1 (0.69) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL272670 | 0.81 | EGLN1 (0.88) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL16790886 | 0.79 | EGLN1 (0.64) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL12599456 | 0.78 | EGLN1 (0.80) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL271606 | 0.78 | EGLN1 (1.00) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL272200 | 0.78 | EGLN1 (1.00) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL12669231 | 0.77 | EGLN1 (0.72) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL273704 | 0.77 | EGLN1 (1.00) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL272502 | 0.77 | EGLN1 (0.71) | EGLN1VEGFAKDM4ETP53CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-8133894-B2 | N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones | AKEBIA THERAPEUTICS INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885KDM4E 249/4885 |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | EGLN1 2861/4885VEGFA 4546/4885KDM4E 4207/4885 |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885KDM4E 249/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885KDM4E 249/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885KDM4E 2523/4885 |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885KDM4E 249/4885 |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885KDM4E 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.